logo
#

Latest news with #NKT

There Aren't Enough Cables to Meet Growing Electricity Demand
There Aren't Enough Cables to Meet Growing Electricity Demand

Bloomberg

time2 days ago

  • Business
  • Bloomberg

There Aren't Enough Cables to Meet Growing Electricity Demand

High-voltage electricity cables are in huge demand around the world, so much so that a lack of cabling has become a bottleneck throttling the clean energy transition. So why are cable manufacturers so hesitant to expand? Also, how are these giant cables made? And is China about to eat everyone's lunch? Claes Westerlind, chief executive officer of cable manufacturing company NKT, joins Zero to discuss. This is the third episode in Bottlenecks, a series exploring the lesser known obstacles standing in the way of our electrified future.

Zero: There Aren't Enough Cables to Meet Power Demand
Zero: There Aren't Enough Cables to Meet Power Demand

Bloomberg

time2 days ago

  • Business
  • Bloomberg

Zero: There Aren't Enough Cables to Meet Power Demand

High-voltage electricity cables are in huge demand around the world, so much so that a lack of cabling has become a bottleneck throttling the clean energy transition. So why are cable manufacturers so hesitant to expand? Also, how are these giant cables made? And is China about to eat everyone's lunch? Claes Westerlind, chief executive officer of cable manufacturing company NKT, joins Zero to discuss. This is the third episode in Bottlenecks, a series exploring the lesser known obstacles standing in the way of our electrified future.

NKT A/S concludes share buyback programme
NKT A/S concludes share buyback programme

Yahoo

time3 days ago

  • Business
  • Yahoo

NKT A/S concludes share buyback programme

Company Announcement 11 June 2025Announcement No. 18 NKT A/S concludes share buyback programme On 21 May 2025, NKT A/S initiated a share buyback programme to meet obligations relating to the Company's share-based incentive programmes for employees and employee share programme, as informed in Company Announcement no. 17 of 21 May 2025. This share buyback programme has now been concluded. The share buyback programme was executed in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules. Between 22 May 2025 and 10 June 2025, NKT A/S has bought back 268,949 shares for a total amount of DKK 146.1m (EUR 19.6m). Trading days Number of shares bought back Average transaction price Amount in DKK 22 May 2025 37,000 519.09 19,206,344.80 23 May 2025 37,000 533.13 19,725,791.50 26 May 2025 28,613 545.00 15,594,022.05 27 May 2025 41,000 564.82 23,157,673.30 28 May 2025 36,387 566.74 20,622,001.13 2 June 2025 20,000 555.72 11,114,314.00 3 June 2025 20,000 525.69 10,513,722.00 4 June 2025 20,000 525.83 10,516,644.00 6 June 2025 20,000 540.20 10,804,064.00 10 June 2025 8,949 542.06 4,850,923.58 Following the transactions stated above, NKT A/S owns a total of 269,594 treasury shares corresponding to 0.50% of the total share capital. Contact InvestorsJacob Johansen, Head of Investor Relations+45 2169 3591 / Louise Westh Naldal, Head of Group Communications+45 2982 0022 / Attachment NKT concludes share buyback programmeError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

NKT initiates share buyback to meet obligations for share-based incentive programmes for employees
NKT initiates share buyback to meet obligations for share-based incentive programmes for employees

Yahoo

time21-05-2025

  • Business
  • Yahoo

NKT initiates share buyback to meet obligations for share-based incentive programmes for employees

Company Announcement 21 May 2025Announcement No. 17 NKT initiates share buyback to meet obligations for share-based incentive programmes for employees Share based incentivesThe Board of Directors of NKT A/S has decided to exercise the authority to buy back shares granted by the Annual General Meeting on 25 March 2021. The authorisation is valid in the period until 31 March 2026, and the Board of Directors is authorised to arrange for acquisition of the Company's own shares up to a nominal value of 10% of the share capital. The share buyback is to meet obligations relating to the Company's share-based incentive programmes for employees. Employee share programmeAt the Annual General Meeting and in Company Announcement No. 14 dated March 19, 2025, NKT announced the anticipated launch of an employee share programme in June. NKT now confirms the launch of the employee share programme in June. The purpose of the share buyback programme is to fulfill the obligations arising from this initiative. The share buyback programme will run from 22 May 2025 and end no later than 20 June 2025. During this period, NKT A/S will buy its own shares up to a maximum of 268,949 shares in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour-rules. Terms NKT A/S is required to retain a lead manager who is to make its own trading decisions independently of and without influence from the Company and execute the share buyback programme within the announced limits. NKT A/S has designated Nordea Denmark, Filial af Nordea Bank Abp, Finland as its lead manager for the share buyback programme. Under the share buyback programme, NKT A/S may repurchase up to 268,949 shares, corresponding to 0.50% of the current share capital of NKT A/S, for an amount up to maximum DKK 175m. No shares may be bought back at a price exceeding the higher of (i) the share price of the latest independent trade and (ii) the highest current independent bid at Nasdaq Copenhagen at the time of trading in compliance with the authority. The maximum number of NKT A/S shares that may be purchased on each business day may not exceed 25% of the average daily trading volume of NKT A/S shares on Nasdaq Copenhagen during the 20 trading days preceding the date of purchase. Contact InvestorsJacob Johansen, Head of Investor Relations+45 2169 3591 / Pelle Fischer-Nielsen, External Communications Lead, +45 2223 5870 / Attachment NKT initiates share buyback

GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase
GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase

Business Upturn

time16-05-2025

  • Business
  • Business Upturn

GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase

By GlobeNewswire Published on May 16, 2025, 18:15 IST Live webcast fireside chat with Marc Hertz, PhD, Chief Executive Officer on Wednesday, May 21 st at 2:40 PM ET LA JOLLA, CA, May 16, 2025 (GLOBE NEWSWIRE) — GRI Bio, Inc. (NASDAQ: GRI) ('GRI Bio' or the 'Company'), a biotechnology company advancing an innovative pipeline of Natural Killer T ('NKT') cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Marc Hertz, PhD, Chief Executive Officer of GRI Bio will participate in a fireside chat at A.G.P.'s Annual Healthcare Company Showcase being held virtually on Wednesday, May 21, 2025 at 2:40 PM ET. Click here to register for the event. A live webcast of the fireside chat will be accessible on the Events page under the Investors section of the Company's website ( About GRI Bio, Inc. GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio's therapies are designed to target the activity of Natural Killer T ('NKT') cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. NKT cells are innate-like T cells that share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. Type I invariant NKT ('iNKT') cells play a critical role in propagating the injury, inflammatory response, and fibrosis observed in inflammatory and fibrotic indications. GRI Bio's lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a serious disease with significant unmet need. The Company is also developing a pipeline of novel type 2 diverse NKT ('dNKT') agonists for the treatment of systemic lupus erythematosus. Additionally, with a library of over 500 proprietary compounds, GRI Bio has the ability to fuel a growing pipeline. Investor Contact:JTC Team, LLCJenene Thomas(908) 824-0775 [email protected] Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store